Member Info for Sisyphus

Couldn't agree more and I'm sure that's why the initial subscription created demand from instos to want to buy in, hence the second one. That's a great indicator of horizon events that we PI's aren't party to and why I go back and re-read any pointers. There is sufficient guarded optimism in the interims and t/u to make me think that Mondays outlook will be a lot more buoyant than is indicated by this oversold MCap. Hardide has managed the oil and gas downturn, it has refilled its coffers over the summer and [importantly] could easily cope with a significant increase in business [upto 500%??] with no further outlay. Given the pipeline of opportunities in trials, as the era of chrome-plating comes to an end Hardide must be a beneficiary. With no expensive stock-holding, this is a pure value-adding technical business with proven and protected IP. Quality niche business and oversold.

Agree totally. Significant support from existing investors [and then new instos at 0.8p in summer] really makes me think they had seen significant horizon events. Two sentences hidden in the interims make me think they may be indicators [especially the ppe order]::::::: viz ::::: However, several important opportunities are now close to completion and we are continuing to work with existing and potential customers on many new and exciting developments that should be the source of further growth in the medium- to long-term. Following successful testing, the Company secured its first large production order to coat components for fracking tools during the period, with a further large order received post-period. In addition we have recently been certified by a major global player on critical subsea flow control components, and are now receiving orders. The coating has also entered development and test in a range of new applications for several oil and gas service and operating companies internationally. I've bought in at this low level as chromium plating is history due to hexavalent toxicity and the ban will come into operation either next year or close afterwards. Eight years testing with BAE and Augusta will bring big ordersafter big and necessary long lead times. Oversold as Monday's outlook [rather than results] should vindicate.

Short-term and day traders are churning out. We are now starting to see concerted buying of bigger packages up from 50k quite nicely to 800k and rising. We should soon start to see m-trades and then multiples as the walls come down and positions start to be taken by serious instos. Correct me by all means in a week or so if I am wrong, but by then it will have been headlined in quite a few journals and press. This is not a sleepy result for Pisces, it is cutting edge in an area at the fore of healthcare concern.

As I said earlier. These results are just beginning to sink in and the effect will snowball. Having been in the 'healthcare arena' for my 40 year career it is good to see boundaries being pushed. Wellcomes work on anti-virally in the late 70's and early 80's took a short time to grasp. The results will be scrutinised by peer reviews in the medical journals and I certainly expect investment analysts are running their eyes over this today. The usual financial press will cover it mid-week to weekend. Make no mistake, it is an important announcement albeit by a tiddler in big Pharma cap terms, but in potential savings on the effects of stroke on healthcare budgets, watch this space. I am quite happy to hold and honestly expect this to be one of a handful of AIM to unicorn stocks given an 18 month horizon. Institutions will have to follow Woodford here and get on board as it 'could' be a game changer IMO.

True; for conventional 'drug' clinical trials. If you read relevant data you will find that because of the need for 'any' treatment option, several jurisdictions are ready to apply super-fast-track status as long as safety profile is good, which Pisces and RP indicate.

The positive results here..............followed by RP........... and then peripheral ischaemia...........then glioma............ the possibilities for Alzheimer's / dementia / etc..... Tuck away and forget [if you can without peeking!]. Excellent stand-alone and a very, very tasty morsel for a bigger player.

Pisces2 was the earthquake...............the tsunami has been created. Its just a matter of time. Tuck away and wait. Once the day-traders and players have had their fun the real value will out; period.

The Pisces2 results are far more far-reaching than any drug phase 1/2 trial. Several RENE trials have shown safety and lack of side-effects. We now have efficacy [as is also indicated in trials with RP]. It is worth bearing in mind that, with rapidly growing age-heavy populations, both Japan and America have indicated that they would essentially put phase1/2 validated SCT into basically a super-orphan drug category for fast adoption. There is currently no treatment or very poor treatment prognosis for areas in which RENE is involved. Tuck away for the future IMO, which may come faster than reactions here indicate; excellent value here.

So oversold now on the basis of those results. I think its the inability of the short termers and traders to actually digest the implications of the results. Give it time; the scientists will lead the charge on this as results go public. Then, the sheep will follow..... £60m cash plus increasingly validated IP looks quite a bargain so I'm accumulating for an uncertain economic outlook. Should be recession proof here.

I'm picking up more on the back of results. Downside now is covered and £60m in the bank gives plenty of room for upgades. This should really fly as the analysts and press work out what just happened IMO.

Short-term traders who bought at bottom will go. The price will the stabilise before climbing as implications of the Pisces2 kick in. Tany weakness just presents an opportunity to buy more IMO. The trials pipeline is excellent going forward and the company is fully funded. I'm a LTH for substantial gains here and top up on any weakness.

Caution was last weeks watchword here. These results are quite remarkable, especially when put into context. It validates all that Reneuron is based upon. It will take time for the implications to be digested as they are published in the medical press. This is cutting-edge therapy with very positive results and will now attract an increasing amount of interest. Stroke is a distressing event and prognosis is not brilliant. It is responsible for bed blocking etc and puts a huge burden onto the health services of a country. Any validated therapy will certainly attract attention, that is why both the US and Japan have put in place fast-track approvement channels. I am looking for a nice consistent and increasingly strong rise from this low level. I am not into big jumps and fall-backs in shareprice, more a sustained recognition of value . The caution of last week has been replaced by unreserved optimism whe I review Pisces2 and the background initial results on RP.

Brain cancer.. Glioma

Stroke is just the first. Then we have RP (retinitis Pigmentosa) due soon, and limb ischaemia due soon, plus trials into gloom a (brain cancer). These should all provide the momentum kicks to a billion pound company IMO. Pisces2 was pivotal as I said last week as it vindicates everything that Reneuron is doing. This is a unicorn company into the 2020's.

"We are delighted that the PISCES II clinical trial has shown our CTX cell therapy candidate has the potential to become a treatment option for patients living with chronic consequences following stroke. We are particularly excited by the response rate seen on the measures relating to disability and activities of daily living, given that these are the most important for patients and their carers. These measures are also the ones viewed by regulatory authorities as most relevant for late-stage clinical development.

This is a unicorn in the making. Give it 12-18 months and stem cell therapy will be seen as mainstream treatment avenue IMO for a variety of currently unmet needs. These results cannot be ignored by the big pharmas for whom this will be increasingly viewed as an essential add-on. Whatever the increase today, it will be seen as minute in 12-18 months IMO and a great tuck away share in an uncertain economic world.

Then sustained upward momentum as these results are digested over coming weeks. Remember that there is no therepeutic treatment available for stroke related disability and this is just one of four separate trials for different conditions being undertaken by Reneuron. A giant in the making IMO.

Wow. These are pivotally significant Pisces2 data results for stem cell therapy. With two thirds of its MCap in cash and groundbreaking results in areas of huge unmet need expect a rush to get on board. If RENE were an oil minnow, it just hit a bn barrel reservoir. Interesting.....very. Woodford's faith in Reneuron was not misplaced at 5p a pop. Japanese and US eyes will certainly focus here given legislative fast tracking for validated SCT. The Retinitis Pigmentosa trials due soon should also be encouraging given these results. One to follow definitely with lots of press coverage to follow now I would think.

AUNboy, they won't know overall results as this is the 3 month early indicator Pices2 is officially end-pointed at 6 months where assessment against specific protocols will be measured. I also agree with other posters that the analyst meeting after the company results and clinical trial update is 'interesting'.

Do the research and look at the other three trial arenas in Reneuron bag; and reflect on the cash in the bank to end 2018. Pisces 2 (looking at the previous excellent indicators) should be the blue touch paper for mainstream acceptance of CST. All the animal studies and modelling showed excellent results in stroke replication and RP. Its application to flip a is also major if proven. Pisces1 showed first rate safety profile on escalating dose regime. Pisces2 should be showing 3 month indicators at this stage referencing the follow-up on patients in Pisces1. It won't only be private investors chasing RENE if good, there will be interest from big instos and major Pharma as CST is potentially game-changing in areas with no therapeutic solution at present. All IMO of course. I think positions have been being taken for some time here since the 5p fundraise in 2015. Interesting on so many fronts here.